Reliability and Validity of the Functional Assessment of Cancer Therapy–Ovarian

Basen-Engquist, Karen; Bodurka, Diane C.; Fitzgerald, M. A.; Webster, Kimberly; Cella, David; Hu, Shaohua; Gershenson, David M.

doi:10.1200/jco.2001.19.6.1809

Cited by 246 publications

(164 citation statements)

References 27 publications

Supporting

Mentioning

155

Contrasting

Unclassified

Order By: Relevance

“…Internal consistency and test-retest reliability of the FACT-O subscale were good. 15 The scale correlated with other measures as expected, and all correlations were in the hypothesized direction. In addition, the FACT-O has been found to be sensitive to improvements in QOL experienced by patients responding to platinum and taxane therapy.…”

Section: Qol Measuressupporting

confidence: 71%

“…This version of FACT-O consists of a 33-item Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire, which is targeted to cancer patients generally, and 12 questions specific to issues faced by ovarian cancer patients. 15,16 Version 2 of the FACT-G questionnaire includes five sub-scales (physical well-being, social well-being, emotional well-being, relationship with doctor, and functional well-being) that can be analyzed separately or aggregated to produce a total QOL score. The FACT-G has demonstrated reliability, validity, and responsiveness to change over time.…”

Section: Qol Measuresmentioning

confidence: 99%

“…In addition, the FACT-O has been found to be sensitive to improvements in QOL experienced by patients responding to platinum and taxane therapy. 15,16 An additional five items (GOG supplemental questions) related to incision (three items), numbness and/or tingling (one item), and weight change (one item) were added to assess treatment-specific concerns in this patient population, approximately half of whom would be randomly allocated to receive interval secondary cytoreduction.…”

Section: Qol Measuresmentioning

confidence: 99%

See 2 more Smart Citations

Quality-of-Life Comparisons in a Randomized Trial of Interval Secondary Cytoreduction in Advanced Ovarian Carcinoma: A Gynecologic Oncology Group Study

Wenzel

Huang

Monk

et al. 2005

JCO

Self Cite

109

View full text Add to dashboard Cite

Purpose-To compare self-reported quality of life (QOL) in patients who did versus did not undergo interval secondary cytoreduction after initial surgery and combination chemotherapy for advanced ovarian cancer and to assess the association between baseline QOL scores and survival.Patients and Methods-Consenting patients participating in a Gynecologic Oncology Group (GOG) phase III treatment trial (GOG 152) completed the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) questionnaire and treatment-specific supplemental questions at the third and sixth chemotherapy cycles and at 6 and 12 months after starting treatment.Results-For all patients, QOL decreased approximately 1 unit from the first to second assessment. Significant improvement observed at 6 months (P < .001) was sustained at 12 months, with no appreciable between-group difference. The baseline FACT-O score was associated with overall survival (P = .048) but not progression-free survival. Less neurotoxicity was reported Address reprint requests to Denise Mackey, Gynecologic Oncology Group, Four Penn Center, 1600 JFK Blvd, Suite 1020, Philadelphia, PA 19103; dmackey@gog.org. Authors' Disclosures of Potential Conflicts of InterestAlthough all authors have completed the disclosure declaration, the following author or their immediate family members has indicated a financial interest. No conflict exists for drugs or devices used in a study if they are not being evaluated as part of the investigation. Author ManuscriptAuthor Manuscript Author ManuscriptAuthor Manuscript among patients who did (38.4%) versus did not (54.0%) undergo interval secondary cytoreduction at the third assessment (P = .005), and older patients experienced more long-term effects.Conclusion-This is the first multicenter randomized trial in ovarian cancer to longitudinally examine self-reported QOL and establish a predictive value of baseline QOL on survival, attributed primarily to the lowest-scoring quartile. Although interval secondary cytoreduction resulted in no notable long-term difference, a clinically significant improvement was seen in both arms at 6 and 12 months after starting therapy. Interestingly, there were fewer complaints of neurotoxicity at 6 months among patients who did versus did not undergo interval secondary cytoreduction.

show abstract

Section: Qol Measuressupporting

confidence: 71%

Section: Qol Measuresmentioning

confidence: 99%

Section: Qol Measuresmentioning

confidence: 99%

See 1 more Smart Citation

Quality-of-Life Comparisons in a Randomized Trial of Interval Secondary Cytoreduction in Advanced Ovarian Carcinoma: A Gynecologic Oncology Group Study

Wenzel

Huang

Monk

et al. 2005

JCO

Self Cite

109

View full text Add to dashboard Cite

show abstract

“…Overall, the sample mean on the SF-12 MCS (52.7) was in the range of the normative score of 50. Similarly, the mean item score of 3.5 on the FACT subscales was comparable to cross-sectional data from validation samples (Basen-Engquist et al, 2001;Janda et al, 2005).…”

Section: Clinical Description Of the Samplesupporting

confidence: 57%

Sexual Self Schema as a Moderator of Sexual and Psychological Outcomes for Gynecologic Cancer Survivors

et al. 2008

View full text Add to dashboard Cite

Gynecologic cancer patients are at high risk for emotional distress and sexual dysfunction. The present study tested sexual self schema as an individual difference variable that might be useful in identifying those at risk for unfavorable outcomes. First, we tested schema as a predictor of sexual outcomes,including bodychangestress. Second,we examined schema as a contributor to broader quality of life outcomes, specifically as a moderator of the relationship between sexual satisfaction and psychological statue (depressive symptoms and quality of life). A cross-sectional design was used. Gynecologic cancer survivors (N = 175) 2−10 years post treatment were assessed during routine follow up. In regression analyses controlling for sociodemographic variables, patients' physical symptoms/signs as evaluated by nurses, health status, and extent of partner sexual difficulties, sexual self schema accounted for significant variance in the prediction of current sexual behavior, responsiveness, and satisfaction. Moreover, schema moderated the relationship between sexual satisfaction and psychological outcomes, suggesting that a positive sexual self schema might "buffer" patients from depressive symptoms when their sexual satisfaction is low. Furthermore, the combination of a negative sexual self schema and low sexual satisfaction might heighten survivors' risk for psychological distress, including depressive symptomatology. These data support the consideration of sexual self schema as a predictor of sexual morbidity among gynecologic cancer survivors.

show abstract

“…Streiner and Norman (1989, p. 44) recommended that items with 80% or more respondents endorsing one category should be excluded from a composite scale. The Quick-FLIC items did not exceed this level and their distributions did not appear to be more concentrated than other cancer HRQoL measures' (eg Basen-Engquist et al, 2001). However, we do not recommend using a few skewed items to assess subdomains of HRQoL; we use all the 11 items to assess overall HRQoL.…”

Section: Discussionmentioning

confidence: 74%

Quick-FLIC: validation of a short questionnaire for assessing quality of life of cancer patients

Cheung

Wong

et al. 2004

Br J Cancer

View full text Add to dashboard Cite

A practically useful measure of quality of life should be simple and quick to complete. A shortened Chinese version of the Functional Living Index -Cancer (FLIC) was recently proposed and was called Quick-FLIC. This study aims to assess the measurement properties of the Quick-FLIC. A total of 190 patients who received care from the National Cancer Centre of Singapore completed a questionnaire package at baseline. Patients filled in a retest questionnaire on average 2 weeks after baseline to assess test -retest reliability and responsiveness to change. The Quick-FLIC scores correlated well with the Functional Assessment of Chronic TherapyGeneral scores (r ¼ 0.78). Patients with different treatment status, performance status and self-rated health had significantly different Quick-FLIC scores in the expected directions (ANOVA; each Po0.001). Internal consistency (Cronbach's alpha ¼ 0.87) and 2-week test -retest reliability (intraclass correlation ¼ 0.81) were also satisfactory. The measure was responsive to changes in health status (Po0.001). The Quick-FLIC is a valid and reliable measure of health-related quality of life of cancer patients. The shortening of established health-related quality of life instruments should be considered in order to reduce the burden of having patients to answer lengthy questionnaires.

show abstract

Reliability and Validity of the Functional Assessment of Cancer Therapy–Ovarian

Abstract: Overall, the FACT-O provides a reliable and valid assessment of the quality of life of women with ovarian cancer, and is appropriate as a brief quality of life assessment in clinical trials and descriptive studies.

Cited by 246 publications

References 27 publications

Quality-of-Life Comparisons in a Randomized Trial of Interval Secondary Cytoreduction in Advanced Ovarian Carcinoma: A Gynecologic Oncology Group Study

Quality-of-Life Comparisons in a Randomized Trial of Interval Secondary Cytoreduction in Advanced Ovarian Carcinoma: A Gynecologic Oncology Group Study

Sexual Self Schema as a Moderator of Sexual and Psychological Outcomes for Gynecologic Cancer Survivors

Quick-FLIC: validation of a short questionnaire for assessing quality of life of cancer patients

Contact Info

Product

Resources

About